New BRCA-targeting drug could treat advanced prostate cancer
Talazoparib delayed disease progression in Phase II trial
Read More
Tag: talazoparib
Talzenna bags EU approval for gBRCA-mutated breast cancer
The indication is for patients with inherited BRCA-mutated locally advanced or metatastatic breast cancer.
Read More
Pfizer’s Talzenna cleared for breast cancer
US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.
Read More
Pfizer files PARP inhibitor for breast cancer in US, EU
Regulators on both sides of the Atlantic have accepted for review Pfizer’s PARP inhibitor talazoparib as a treatment for women with a hereditary BRCA mutation.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
